AMRI is brightening its expectations for 2015 after closing its latest buyout, counting on its manufacturing division to keep revenue rolling.
Contract drugmaker AMRI signed a deal with Italy's Saneca Pharmaceuticals to collaborate on opium-derived treatments, pairing up with eyes on the U.S. market for controlled substances.
AMRI, the Albany, NY-based company that has been moving away from drug discovery toward manufacturing, said it's teaming with Saneca Pharmaceuticals of Slovakia to produce and sell a suite of opium-derived APIs.
New York-based CMO AMRI has seen its contract manufacturing grow big time after picking up a number of competitors. CEO William Marth says after its latest deal for a Spanish specialty drugmaker, that growth should carry through the year.
AMRI, rebuilding its business after a string of slow quarters, posted a profit for the first time in 12 months as it looks to hit its stride as a growing contract drug developer.
Contract drugmaker AMRI paid $174 million for a Spanish manufacturing operation, part of the company's long-term plan to dial up its focus on production.
Albany, NY-based contract manufacturer AMRI has continued its buying spree for more and more diverse manufacturing capacity, and the deals are getting larger. Its latest is a $174 million deal for a drugmaker in Spain that makes specialty APIs and sterile injected drugs.
Contract drug developer AMRI bought Spain's Gadea Pharmaceutical for $174 million, picking up a company focused on the manufacture of active ingredients and finished treatments.
AMRI, in the process of consolidating its drug discovery services, is teaming up with life sciences giant PerkinElmer to accelerate a new biomedical hub in Buffalo, NY.
Contract drugmaker AMRI is shifting some of its focus to early-stage R&D, partnering up with a neighboring biotech to expand its capabilities in drug discovery.